TY - JOUR
T1 - Clinical Outcomes and Prognostic Factors of Patients With Early Malignant Melanoma in One Latin American Country
T2 - Results of the Epidemiological Registry of Malignant Melanoma in Colombia Study
AU - Ospina Serrano, Aylen Vanessa
AU - Contreras, Fernando
AU - Triana, Iván
AU - Sánchez-Vanegas, Guillermo
AU - Ortíz, Juan David
AU - Ramos, Pedro
AU - Vargas, Claudia
AU - Arango, Natalia
AU - Idrobo, Henry
AU - Munévar, Isabel
AU - Yepes, Andrés
AU - Mantilla, William
AU - Jiménez, Paola
AU - Rivas, Giovanna
AU - Lema, Mauricio
AU - Alcalá, Carmen
AU - Gómez, Diego
AU - Chinchia, Matilde
AU - Barrero, Angela
PY - 2023/5/1
Y1 - 2023/5/1
N2 - To describe the population with early malignant melanoma, we performed a cohort study on the basis of the Epidemiological Registry of Malignant Melanoma in Colombia-Asociacion Colombiana de Hematologia y Oncologia. From January 2011 until December 2021, 759 patients were included; the average age was 66 years, 57% were women, acral lentiginous histology was found in 27.8% of patients, and the median follow-up was 36.5 months. The prognostic factors for overall survival in our population are Eastern Cooperative Oncology Group 3-4 (hazard ratio [HR], 13.8), stage III (HR, 5.07), received radiotherapy (HR, 3.38), ulceration on histology (HR, 2.68), chronic sun exposure (HR, 2.3), low income (HR, 2.04), previous local surgery (HR, 0.27), and have received adjuvant treatment (HR, 0.41).
AB - To describe the population with early malignant melanoma, we performed a cohort study on the basis of the Epidemiological Registry of Malignant Melanoma in Colombia-Asociacion Colombiana de Hematologia y Oncologia. From January 2011 until December 2021, 759 patients were included; the average age was 66 years, 57% were women, acral lentiginous histology was found in 27.8% of patients, and the median follow-up was 36.5 months. The prognostic factors for overall survival in our population are Eastern Cooperative Oncology Group 3-4 (hazard ratio [HR], 13.8), stage III (HR, 5.07), received radiotherapy (HR, 3.38), ulceration on histology (HR, 2.68), chronic sun exposure (HR, 2.3), low income (HR, 2.04), previous local surgery (HR, 0.27), and have received adjuvant treatment (HR, 0.41).
UR - http://www.scopus.com/inward/record.url?scp=85159837886&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/4d1997c7-a07e-3fb5-a59d-386f513e1c3a/
U2 - 10.1200/GO.22.00377
DO - 10.1200/GO.22.00377
M3 - Artículo
C2 - 37216624
AN - SCOPUS:85159837886
SN - 2687-8941
VL - 9
SP - e2200377
JO - JCO global oncology
JF - JCO global oncology
IS - 9
ER -